Editing CUA: Muscle-invasive Bladder Cancer (2019) (section)

== Questions (includes 2017 AUA MIBC Guidelines content) ==

# Based on the control arms of trials evaluating NAC in MIBC, what is the approximate pT0 rate in patients undergoing RC without NAC?
# What are the recommended chemotherapy regimen options for NAC?
# BONUS: describe SWOG 8710
# What are the components of MVAC?
# What is the mechanism of action of gemcitabine? Cisplatin?
# What toxicities are associated with cisplatin?
# What is the OS benefit of NAC?
# What are the absolute contraindications to NAC? Relative?
# What is the preferred management of patients with contraindications to NAC?
# A patient agrees to undergo NAC with GC. When will you see them next in follow-up?
# When should a patient undergo radical cystectomy after receiving NAC?
# If a patient does not receive NAC, who should be referred for adjuvant chemotherapy?
# If a patient does not receive NAC, when should the cystectomy be done in relation to timing of the TURBT?
# What are the indications for a urethrectomy as per the CUA MIBC guidelines?
# As per the CUA MIBC guidelines, what patients are ideal for TMT?
# What are the ideal characteristics to consider partial cystectomy in MIBC?
# As per the AUA MIBC guidelines, what are the absolute contraindications to a continent diversion?
# What are the most common sites of metastasis?
# As per the AUA MIBC guidelines, which laboratory investigations should be ordered during the follow-up of a patient treated for MIBC?